KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) EBT (2016 - 2025)

Thermo Fisher Scientific's EBT history spans 17 years, with the latest figure at $2.2 billion for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 10.92% year-over-year to $2.2 billion, compared with a TTM value of $7.3 billion through Dec 2025, up 3.85%, and an annual FY2025 reading of $7.3 billion, up 3.85% over the prior year.
  • EBT for Q4 2025 was $2.2 billion at Thermo Fisher Scientific, up from $1.8 billion in the prior quarter.
  • The five-year high for EBT was $2.8 billion in Q2 2021, with the low at $1.4 billion in Q2 2023.
  • Average EBT over 5 years is $1.9 billion, with a median of $1.8 billion recorded in 2022.
  • Year-over-year, EBT soared 232.49% in 2021 and then plummeted 46.34% in 2023.
  • Tracing TMO's EBT over 5 years: stood at $1.9 billion in 2021, then dropped by 4.56% to $1.8 billion in 2022, then dropped by 2.08% to $1.7 billion in 2023, then rose by 11.55% to $1.9 billion in 2024, then grew by 10.92% to $2.2 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's EBT are $2.2 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.7 billion (Q2 2025).